StoxGland Pharma vs Ajanta Pharmaceuticals: share price & financials comparison
NSE: GLAND vs AJANTPHARM · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Gland Pharma vs Ajanta Pharmaceuticals at a glance
Gland Pharma (GLAND) has a market capitalisation of ₹55,016 Cr, against ₹41,165 Cr for Ajanta Pharmaceuticals (AJANTPHARM). Over the past year Gland Pharma has returned +74.4%, compared with +25.8% for Ajanta Pharmaceuticals. On valuation, Ajanta Pharmaceuticals trades at a lower P/E of 32.7 versus 44.5. Ajanta Pharmaceuticals earns a higher return on equity (25.9% vs 11.6%). Gland Pharma comes out ahead on financial health, momentum and technicals. Ajanta Pharmaceuticals comes out ahead on size, valuation, profitability and growth. Across the scored metrics below, Gland Pharma leads on 9 and Ajanta Pharmaceuticals on 8. On StoxGud's 10-point checklist, Gland Pharma scores 8/10 and Ajanta Pharmaceuticals scores 9/10.
| Metric | Gland Pharma | Ajanta Pharmaceuticals |
|---|---|---|
| Size | ||
| Market cap | ₹55,016 Cr | ₹41,165 Cr |
| Revenue (latest FY) | ₹6,431 Cr | ₹5,453 Cr |
| Net profit (latest FY) | ₹1,027 Cr | ₹1,056 Cr |
| Valuation | ||
| P/E | 44.5 | 32.7 |
| P/B | 5.15 | 8.47 |
| Dividend yield | 0.54% | 0.85% |
| Profitability | ||
| Return on equity | 11.6% | 25.9% |
| Net profit margin | 17.5% | 20.2% |
| Operating margin | 27.2% | 27.1% |
| Growth | ||
| Revenue growth (YoY) | +23.3% | +32.5% |
| Net profit growth (YoY) | +58.3% | +49.2% |
| Revenue CAGR (multi-year) | +13.2% | +13.5% |
| Financial health | ||
| Debt to equity | 0.02 | 0.02 |
| Momentum | ||
| 1-month return | +7.9% | -1.3% |
| 1-year return | +74.4% | +25.8% |
| 3-year CAGR | +27.0% | +20.7% |
| 5-year CAGR | -1.7% | +17.8% |
| 10-year CAGR | — | +11.2% |
| Distance from 52W high | +0.0% | -11.7% |
| Technicals | ||
| RSI (14) | 88 | 50 |
| Price vs 200-day avg | +42.4% | +2.9% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Gland Pharma | Ajanta Pharmaceuticals |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 8/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Gland Pharma or Ajanta Pharmaceuticals?
Gland Pharma has a market cap of ₹55,016 Cr and Ajanta Pharmaceuticals has a market cap of ₹41,165 Cr as of 13 Nov 2026.
Which has a lower P/E, Gland Pharma or Ajanta Pharmaceuticals?
Ajanta Pharmaceuticals has the lower P/E: Gland Pharma trades at 44.5 and Ajanta Pharmaceuticals at 32.7.
Which gave better returns in the last year, Gland Pharma or Ajanta Pharmaceuticals?
Gland Pharma did better: Gland Pharma returned +74.4% and Ajanta Pharmaceuticals returned +25.8% over one year.
What is the difference between Gland Pharma and Ajanta Pharmaceuticals?
Both are NSE-listed companies in Healthcare. Gland Pharma is about 1.3 times the size of Ajanta Pharmaceuticals by market cap. In the latest financial year Gland Pharma reported revenue of ₹6,431 Cr and Ajanta Pharmaceuticals ₹5,453 Cr. Operating margin is 27.2% for Gland Pharma and 27.1% for Ajanta Pharmaceuticals. Debt to equity is 0.02 for Gland Pharma and 0.02 for Ajanta Pharmaceuticals.
Which is better, Gland Pharma or Ajanta Pharmaceuticals?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Gland Pharma leads on 9 and Ajanta Pharmaceuticals on 8. Gland Pharma is ahead on financial health, momentum and technicals. Ajanta Pharmaceuticals is ahead on size, valuation, profitability and growth. On StoxGud's rules-based checklist Gland Pharma scores 8/10 and Ajanta Pharmaceuticals scores 9/10. This is information, not advice: consult a SEBI-registered adviser before investing.